Gli-2 expression was associated with poor prognosis of hepatocellular carcinoma by 곽재문
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Background and Aims: The Sonic hedgehog (SHH) pathway acts as a 
regulator of development, homeostasis, and reparative processes in 
endodermal tissues, including the gastrointestinal tracts. Abnormal 
expression or mutation of SHH components has been reported in 
esophageal, gastric, duodenal, and pancreatic cancers. SHH-pathway-
targeted therapies have been developed and applied in the management 
of  upper-GI tract cancer. We aimed to study the expression status of 
several molecules in the SHH signal pathway in hepatocellular 
carcinoma (HCC) and the clinicopathologic features of HCCs according 
to their expression status.  
Methods: We assessed the expression status of the SHH ligand, Patched 
(PTCH), and oncogenes (Gli-1, Gli-2 and Gli-3) by 
immunohistochemistry in 407 HCCs blocked in 13 tissue microarrays 





Results: The positive rates for SHH, PTCH, Gli-1, Gli-2 and Gli-3 were 
49.1%, 10.1%, 1.5%, 17.0%, and 1.5%, respectively. Comparative 
analysis with clinicopathologic parameters revealed that the positive 
expression rate for SHH was higher in males than in females and was 
higher in patients whose preoperative alpha-fetoprotein level was 
higher than normal (all p < 0.05). Gli-2 expression was prominent in 
females and in patients whose tumor had a high Edmondson-Steiner 
nuclear grade , dedifferentiated histology (e.g., solid or spindle cell 
morphology), high pT stage, and CK19 positivity (all p < 0.05). The 
expression levels of PTCH, Gli-1 and Gli-3 were not associated with a 
significant difference in tumor features. Only positive Gli-2 expression 
was associated with a shorter disease-free survival (DFS) and overall 
survival (OS) time (10 vs 34 months, 53 vs 181 months, all p < 0.05). 
Gli-2 expression was an independent prognostic factor according to 




multiplicity, size and extent of invasion (p = 0.015).  
Conclusion: The results suggest that Gli-2 could be an independent 
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Hepatocellular carcinoma (HCC) is the fifth- most common cancer in the 
world and the third-most common cause of mortality. In addition, there is 
a high percentage of patients with poor prognoses suffering from the 
intermediate or advanced stages of HCC.[1]   
There are several mechanisms associated with the tumorigenesis of HCC. 
The Sonic hedgehog (SHH) pathway has been shown to be an important 
pathway in embryogenesis and a diverse variety of cancers of human 
cancers.[2-5] The hedgehog pathway was first identified in Drosophila 
during a screen for genes concerning early embryonic development[6] and 
has three ligands (Sonic, Indian, and Desert hedgehog). The SHH pathway 
plays a significant role in the initiation and invasion of HCC.[7] 
The SHH pathway can be described as follows. The Sonic hedgehog 
ligand binds to the membranous receptor, patched (PTCH), leading to the 
activation of the suppressed smoothened(SMO) molecule and consequent 
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triggering of the intracellular mechanisms that activate glioma-
associated-oncogenes (Gli-1, Gli-2 and Gli-3).[8] 
Gli has already been proven to be an important molecule in human 
HCC.[9] Furthermore, the selective down-regulation of Gli-2 inhibits the 
proliferation of hepatocellular carcinoma cells. Therefore, we can presume 
that the SHH pathway is important in HCC tumorigenesis. [9] However, 
there are only a few studies that have examined the correlations between 
SHH pathway molecule expression and HCC prognosis, including disease-
free or overall survival. 
Thus, there is a growing need to study the SHH pathway molecules in 
association with prognostic factors to develop more specific targeted 
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Objectives 
The goal of this study was to investigate the expression frequency and 
correlation with clinicopathologic features of the SHH pathway molecules 
in HCC tissues and to analyze their influence on the disease-free survival 
and overall survival.  
 
Materials and Methods 
1. Patients 
The specimens used in this study were surgically resected at Seoul 
National University Hospital, from 1998 to 2005, and diagnosed as 
hepatocellular carcinoma. We collected cases by slide review after 
searching pathologic reports and medical records, and selected 407 
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2. Analysis of clinicopathologic features 
All cases were reviewed by a pathologist. In addition, the patient 
medical records were examined to confirm clinicopathologic features such 
as age, sex, and type of preoperative treatment. We also re-examined 
pathologic features such as pathologic stage, histologic type, cell type, 
Edmondson-Steiner nuclear grade, gross type, and vascular invasion. The 
tumors were classified according to the WHO classification. To analyze 
overall survival and follow-up, we took advantage of the date of surgery 
for the beginning of the follow-up period. Follow-ups were continued until 
December 31, 2005. 
 
3. Manufacturing tissue microarrays 
We chose formalin-fixed paraffin-embedded blocks containing 
representative tumor sections of 407 cases of hepatocellular carcinoma, 
and manufactured slides with tissue microarrays (4 μm), including up to 60 
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tissue cores in one slide. 
 
4. Immunohistochemistry process and evaluation  
4.1. Antibodies 
For this study, we used SHH-, PTCH-, Gli-1-, Gli-2- and Gli-3-specific 
antibodies to target SHH pathway members. Information about each 
antibody is listed in Table 1. 
4.2. Immunostaining process  
The specimen sample sections were prepared using a Bond Polymer 
Detection Kit and Leica Bond-Max Autostainer (Leica Microsystems 
GmbH, Wetzler, 35578, Germany). First, the samples were deparaffinised 
and hydrated. The samples were placed in pH 6.0 citrate buffer or pH 9.0 
Tris-EDTA buffer at 100℃ for 15 minutes. For blocking endogenous 
peroxidase activity, the samples were incubated in 3% hydrogen peroxide 
for 6 minutes and incubated for 30 minutes for protein blocking. The 
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samples were incubated with the relevant primary antibodies for 1 hour at 
room temperature. The samples were then incubated with a secondary 
antibody biotinylated anti-goat IgG for 30 minutes. Next, the samples 
were incubated with ABC reagent for 30 minutes. Finally, the samples 
were incubated with DAB substrate kit reagents for 2 minutes and then 
counterstained.  
4.3. Evaluation of immunohistochemical results 
Positive expression rate was assessed using two methods. For SHH and 
PTCH, only diffuse cytoplasmic positivity was considered positive. The 
assessment of Gli transcription factors (Gli-1, Gli-2 and Gli-3) was 
considered positive when the percentage of positive cells was more than 
10% of tumor cells.[10]  The cut-off values for the immunohistochemical 
scores are listed in Table 2. 
 
5. Statistical analysis 
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The Statistical Package for the Social Sciences (SPSS) version 19.0 for 
Windows (SPSS Inc., Chicago, IL, U.S.A.) was used for statistical analysis. 
The assessment of the relationship between the positive SHH-pathway 
molecule expression and patient’s clinicopathologic factors was performed 
using the chi-square test. Survival analysis for disease-free survival and 
overall survival was conducted and verified using the Kaplan-Meier 
product-limit method. Differences that were meaningful in the univariate 
analysis were also used in a Cox proportional hazards regression model. 
We defined a positive correlation as being present when the p-value was 
less than 0.05. 
 




1. Expression frequency of SHH pathway molecules in HCC 
 Out of 407 cases, SHH, PTCH, Gli-1, Gli-2 and Gli-3 were expressed in 
the following number of samples: 49.1% (200), 10.1% (41), 1.5% (6), 
17.0% (69), 1.5% (6), respectively.  
 
2. Relationship between the SHH pathway and clinicopathologic features 
We investigated correlations of age, sex, operational method, tumor size, 
tumor multiplicity, gross type, vascular invasion, Edmondson-Steiner 
nuclear grade, histologic pattern, cell type, co-expression with biliary 
phenotype, invasion to adjacent tissue, pathologic T stage, etiology of 
underlying hepatitis, fibrosis extent of background liver, and preoperative 
treatment with the expression of SHH pathway molecules. The median 
values of preoperative alpha-fetoprotein level, disease-free survival and 
overall survival were determined both for high-expression and no-
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expression cases. There were distinct clinical correlations of Gli-2 
positivity with clinicopathologic factors such as Edmondson-Steiner 
nuclear grade, cell type, biliary phenotype, and pathologic T stage. Gli-2 
expression was also well correlated with disease-free survival and overall 
survival (Table 3). 
 
3. Analysis of survival curve according to Gli-2 expression 
The average follow-up period of the total 407 patients was 181 months. 
We analyzed the correlation of the SHH pathway molecules and disease-
free survival of patients with Kaplan-Meyer univariate analysis, and only 
Gli-2 presented a meaningful relationship (positive vs negative: 10 vs 34 
months, p = 0.008). In contrast, the other examined pathway molecules 
had no relation with prognosis (Table 3). The correlation with overall 
survival of patients was also significant only in the case of positive Gli-2-
expressing HCC patients (positive vs negative: 53 vs 181 months, p = 
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0.003). 
Among the clinicopathologic features of HCC, Edmondson-Steiner 
nuclear grade, vascular invasion, tumor multiplicity, tumor size, and extent 
of invasion were well correlated with disease-free survival and overall 
survival. Therefore, we analyzed these factors with a multivariate analysis 
using a Cox proportional hazards regression model. As a consequence, 
Gli-2 was determined to be an independent prognostic factor, as were all 
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Discussion 
The hedgehog signaling pathway plays an important role in various 
human tumor types, including gastric cancer, prostate cancer, lung cancer, 
esophageal cancer, and breast cancer.[11-15] Among the molecules of the 
SHH pathway, Gli-1, Gli-2 and Gli-3 participate as important transcription 
factors. Previous studies have demonstrated that the molecules of the 
SHH pathway are prognostic parameters of human gliomas, especially the 
Gli transcription factors.[10] Similarly, another study found that the 
overexpression of Gli-2 is responsible for the progression of HCC, and 
selective down-regulation of Gli-2 inhibits the proliferation of HCC tumor 
cells.[9] These results suggest Gli-2 may possibly be an HCC prognostic 
factor. Lin et al[16] examined the downstream target genes of Gli-2 and 
reported that FoxM1 (forkhead-box transcription factor M1) is up-
regulated by Gli-2 and modulates cell cycle progression, which 
consequently increases tumor grade and stage.   
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In the present study, we examined the expression status of some of the 
molecules of the SHH signaling pathway. SHH protein, PTCH and Gli-2 
were well expressed in our samples, but the Gli-1 and Gli-3 expression 
levels were relatively low. Accordingly, high SHH protein, PTCH and Gli-2 
expression levels can be considered important factors in human HCC.  
In particular, high Gli-2 expression was associated with dedifferentiated 
histologic features, represented by high Edmondson-Steiner grade, 
pathologic T stage and CK19 expression. These results can augment the 
possibility of Gli-2 serving as a prognostic factor because CK19 positivity 
has been associated with a poor HCC prognosis.  Zhuang et al [17] found 
that CK19 positivity is an independent risk factor of lymph node 
metastasis for HCC and also an independent prognostic factor. Chung et 
al[18] demonstrated that CK19 is more expressed in hypovascular 
hepatocellular carcinomas than in hypervascular carcinomas. Accordingly 
CK19 is a useful prognostic marker of early recurrence and poor survival 
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of HCC patients. 
We found that a poor prognosis was more common in patients having 
tumors co-expressing Gli-2 and CK19. On the other hand, these results 
have the potential of aiding with the development of specific and combined 
targeted HCC therapies. However, there are few studies on the actual 
relationship between CK19 positivity and Gli-2 activity nor their co-
expression and prognostic influence. Thus, additional studies on this 
subject need to be performed.  
Cox-2 multivariate regression analysis revealed that among the SHH 
pathway molecules, only Gli-2 was an independent prognostic factor. In 
addition, high Edmondson-Steiner nuclear grade, vascular invasion, 
tumour multiplicity, tumour size and extent of tumour invasion were 
related to poor prognosis. Our results indicated the same results in 
regards to disease-free survival and overall survival. Therefore, even 
after disease recurrence, Gli-2 can be a meaningful therapeutic target. 
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Vascular invasion and tumour multiplicity are components of a high 
pathologic T stage. Gli-2 expression and high T stage were well-
correlated, however, each individual component, such as vascular invasion 
and tumour multiplicity, did not present a correlation with Gli-2 
expression. Thus, further studies are needed on the pathological changes 
associated with vascular invasion accompanying tumour multiplicity in 
HCC. 
There are various possible mechanisms through which Gli-2 activates 
and facilitates a poor prognosis. One of these mechanisms was revealed 
by Lin et al[16]. Gli-2 can also accelerate cell cycle progression via 
transition through the G(2)-M cycle, in the case of prostate cancer.[12] 
Another cellular mechanism is necessary explain the results found in this 
study. 
The hedgehog pathway is associated not only with HCC, but also with 
various types of liver diseases, including primary biliary cirrhosis.[19] 
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Therefore, additional studies are required to fully elucidate the 
relationship of the hedgehog pathway with other liver carcinomas and 
severe liver diseases, such as cholangiocarcinoma and primary biliary 
cirrhosis. Naturally, the goal of these studies should be the elaboration 
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Conclusion 
Several studies are in progress with a goal of elucidating the molecules 
and pathways that play an important role in the carcinogenesis of HCC. 
 We studied the relationships of selected SHH pathway molecules: SHH 
protein, PTCH, Gli-1, Gli-2 and Gli-3. Gli-2 demonstrated relationship 
with the clinicopathologic factors of HCC patients and was an independent 
prognostic factor.  
CK19, a known indicator of poor HCC prognosis, was co-expressed with 
Gli-2 in our specimens. Therefore, Gli-2 should be considered as an 
important target for molecular therapy, especially in the case of HCC 
patients with a poor prognosis.  
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Table 1. Antibodies used in this study 
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Table 3. Association of SHH molecule expression with 




SHH (+) p value PTCH (+) p value Gli-1 (+) p value Gli-2 (+) p value Gli-3 (+) p value 
Age (year, mean) 
(+) vs (-) 
54.7 vs 54.3 0.500 57.3 vs 54.2 0.149 55.7 vs 54.5 0.779 55.7 vs 54.3 0.416 56.7 vs 54.5 0.593 
Gender 
          
male 
(n=344) 
































Size (cm, mean) 
(+) vs. (-) 
5.4 vs 5.4 0.730 6.1 vs 5.3 0.397 4.9 vs. 5.4 0.617 5.7 v 5.4 0.092 4.3 vs 5.4 0.435 
Multiplicity 
          
single lesion 
(n=307) 
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absent 
(n=213) 
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pT1 (n=171) 83 (48.5) 0.929 15 (8.8) 0.578 4 (2.3) 0.564 25 (14.6) 0.019 4 (2.3) 0.362 

































          
HBV 
(n=290) 
144 (49.7) 0.075 28 (9.7) 0.715 4 (1.4) 0.979 54 (18.6) 0.732 3 (1.0) 0.963 
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Table 4. Kaplan-Meier survival analysis of 












Clinicopathologic factor p value 
Gender 0.479 
Multiplicity 0.001 
Gross type 0.073 
Vascular invasion <0.001 
ES nuclear grade <0.001 
Histologic pattern 0.149 
Cellular type 0.520 
Extent of invasion <0.001 
Underlying hepatitis 0.319 
Fibrosis of background liver 0.363 
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Table 5. Gli-2 expression as an independent prognostic 
factor by according to multivariate Cox analysis 
 
 
Factor p value Exp(B) 95% CI for Exp(B) 
ES nuclear grade 0.038 1.24 [1.01 1.52] 
Vascular 
invasion 
0.029 1.36 [1.03 1.79] 
Multiplicity 0.022 1.39 [1.04 1.86] 
Size 0.003 1.05 [1.01 1.09] 
Extent of 
invasion 
<0.001 1.36 [1.17 1.58] 
Gli-2 positivity 0.015 1.49 [1.07 2.06] 
 
 





SHH(+)                               SHH(-) 
 
 
PTCH(+)                             PTCH(-) 
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Gli-1(+)                              Gli-1(-) 
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Gli-3(+)                              Gli-3(-) 
 
Figure 1. Expression of SHH pathway molecules in HCC.  SHH and PTCH 
were considered positive when more than 50% of tumour cells were 
stained. Gli-1, Gli-2 and Gli-3 were considered positive when more than 
10% of tumour cells were stained. SHH, sonic hedgehog; HCC, 
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Figure 2. Disease free survival & overall survival according to Gli-2 
expression. HCC patients with Gli-2 expression presented significantly 
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Sonic hedgehog(SHH) 신호전달계는 위장관 계통을 포함한 여러 내배엽 
기원의 조직에서 발육, 항상성 유지, 치유활동 등에 조절인자로서 관여한다. 
SHH 신호전달 관련 물질들의 비정상적인 발현 및 돌연변이가 식도, 위장, 
십이지장,  췌장암 등에서 보고되었다. 이러한 SHH 신호전달 관련 물질을 
표적으로 하는 치료법이 개발되어 현재 상부 위장관암의 치료에 응용되고 
있다. 본 연구에서는 간세포암에서 SHH 신호전달계에 관여하는 인자들의 
발현 양상과 임상-병리학적 특성과의 상관 관계를 알아보고자 하였다.  
외과적으로 절제되어 얻은 407개의 간 세포암 조직을 이용하여 13개 
블럭의 미세조직배열 슬라이드를 제작하고 SHH 신호전달계에 관여하는 
요소인 SHH 리간드 (SHH), Patched (PTCH), Gli-1, Gli-2, Gli-3에 대한 
면역조직화학염색을 시행하였다.  
간세포암 조직에서 SHH, PTCH, Gli-1, Gli-2, Gli-3의 발현율은 각각 
49.1%, 10.1%, 1.5%, 17.0% 및 1.5%였으며 임상-병리학적 양상을 분석한 
결과 SHH의 발현은 남성 환자, 담관암이 동반된 경우, 섬유주 양상의 
조직학적 특성을 가진 조직에서 높게 나타났다. Gli-2 발현은 여성 환자, 
높은 Edmonson-Steiner 핵 등급, 고형성 또는 방추형 세포 형태와 같은 
미분화된 조직학적 특성, 높은 T 스테이지, CK19 양성인 경우와 관련성이 
높았다.  PTCH, Gli-1, Gli-3도 비슷한 양상을 보였다.  
SHH 신호전달계에 관련된 여러 인자 중 Gli-2의 양성 발현만이 무병 
생존률 및 전체 생존률과 연관이 있었으며, 콕스 다변량 분석상 독립적인 
 
- 34 - 
 
예후인자로 작용하였다.  
따라서 Gli-2는 간세포암의 예후를 예측할 수 있는 독립적 인자이며, 표적 
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